Given the fact that, clinically, less than 25% of CRC patients benefit from anti-PD1/PD-L1 immunotherapy, a combination with the FXR agonist and PD-L1 immune checkpoint blockade might improve the efficacy of immunotherapy in CRC patients. The gene discussed is CD274; the disease is colorectal carcinoma.